Drug-induced Acute Pancreatitis: A Real-world Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
In this study, we provided the current comprehensive landscape of AP culprit-drugs from the pharmacovigilance perspective, which can provide reference information for clinical practice.PMID:38069538 | DOI:10.1002/cpt.3139 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - December 9, 2023 Category: Drugs & Pharmacology Authors: Dongxuan Li Hongli Wang Chunmeng Qin Dan Du Yalan Wang Qian Du Songqing Liu Source Type: research
Effect of metformin combined with DPP-4 inhibitor on alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis
CONCLUSIONS: Metformin combined with DPP-4 inhibitor can increase alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis, effectively improve periodontal clinical and serum biochemical indicators, and reduce periodontal inflammation.PMID:38044737 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - December 4, 2023 Category: Dentistry Authors: Ke Liu Aniwa Ahemaiti Kebier Tuernisaguli Awut Gulinuer Source Type: research
Effect of metformin combined with DPP-4 inhibitor on alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis
CONCLUSIONS: Metformin combined with DPP-4 inhibitor can increase alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis, effectively improve periodontal clinical and serum biochemical indicators, and reduce periodontal inflammation.PMID:38044737 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - December 4, 2023 Category: Dentistry Authors: Ke Liu Aniwa Ahemaiti Kebier Tuernisaguli Awut Gulinuer Source Type: research
Effect of metformin combined with DPP-4 inhibitor on alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis
CONCLUSIONS: Metformin combined with DPP-4 inhibitor can increase alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis, effectively improve periodontal clinical and serum biochemical indicators, and reduce periodontal inflammation.PMID:38044737 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - December 4, 2023 Category: Dentistry Authors: Ke Liu Aniwa Ahemaiti Kebier Tuernisaguli Awut Gulinuer Source Type: research
Effect of metformin combined with DPP-4 inhibitor on alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis
CONCLUSIONS: Metformin combined with DPP-4 inhibitor can increase alveolar bone density in patients with type 2 diabetes mellitus and chronic periodontitis, effectively improve periodontal clinical and serum biochemical indicators, and reduce periodontal inflammation.PMID:38044737 (Source: Shanghai Journal of Stomatology)
Source: Shanghai Journal of Stomatology - December 4, 2023 Category: Dentistry Authors: Ke Liu Aniwa Ahemaiti Kebier Tuernisaguli Awut Gulinuer Source Type: research
Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials
CONCLUSION: Evidence from the post-marketing safety data analysis identified a strong association between incretin mimetics and pancreatic events. Fewer events in RCTs may justify insignificant meta-analysis results.PMID:37986140 | DOI:10.1080/14740338.2023.2284992 (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - November 21, 2023 Category: Drugs & Pharmacology Authors: Asif Muhammad Christy Thomas Vivekanandan Kalaiselvan Krishna Undela Source Type: research
Controlling Pharmaceutical Costs in a Student-Run Free Clinic in a Resource-Limited Patient Setting
In this study, we aimed to analyze the financial impact of these measures on the clinic.A query of clinic data over the past 5 years identified 299 active PDAPs, corresponding to 299 fully-subsidized prescriptions. In 2017, there were 35 active PDAPs, increasing to 52 (2018), 62 (2019), and 82 (2020) before a decline to 68 PDAPs in 2021. The company affiliated with the most PDAPs varied annually: GlaxoSmithKline (2017), Lilly (2018, 2019, 2020), and both GlaxoSmithKline and Lilly (2021). The most frequent medications were sitagliptin (2017), insulin (2018, 2019), albuterol (2017, 2018), and dulaglutide (2020, 2021).In addi...
Source: Journal of Community Health - November 14, 2023 Category: International Medicine & Public Health Source Type: research
Efficacy and Safety of Switching from Sitagliptin to Ipragliflozin in Obese Japanese Patients with Type 2 Diabetes Mellitus: A Single-Arm Multicenter Interventional Study
ConclusionsSwitching from sitagliptin to ipragliflozin did not alter HbA1c in obese patients with type 2 diabetes, while improving parameters related to organ homeostasis. These data provide novel information useful for selecting oral anti-diabetic agents for patients with type 2 diabetes with obesity, a risk factor for developing various complications of diabetes.Clinical Trial RegistrationJapan Registry of Clinical Trials identifier: jRCT#031190022 (Source: Clinical Drug Investigation)
Source: Clinical Drug Investigation - November 7, 2023 Category: Drugs & Pharmacology Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Curr Diabetes Rev. 2023 Oct 5. doi: 10.2174/0115733998261903230921102620. Online ahead of print.ABSTRACTDiabetes mellitus is an irreversible, chronic metabolic disorder indicated by hyperglycemia. It is now considered a worldwide pandemic. T2DM, a spectrum of diseases initially caused by tissue insulin resistance and slowly developing to a state characterized by absolute loss of secretory action of the β cells of the pancreas, is thought to be caused by reduced insulin secretion, resistance to tissue activities of insulin, or a combination of both. Insulin secretagogues, biguanides, insulin sensitizers, alpha-glucosidase ...
Source: Current Diabetes Reviews - October 27, 2023 Category: Endocrinology Authors: Abhishek Kumar Rupa Mazumder Anjna Rani Pratibha Pandey Navneet Khurana Source Type: research
